Negara: Irlandia
Bahasa: Inggris
Sumber: HPRA (Health Products Regulatory Authority)
OMEGA-3-ACID ETHYL ESTERS
B & S Healthcare
OMEGA-3-ACID ETHYL ESTERS
1000 Milligram
Capsules, Soft
Product subject to prescription which may be renewed (B)
Withdrawn
2013-01-08
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Omacor 1000 mg Soft Capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains Omega-3-acid ethyl esters 90-1000 mg comprising 840 mg eicosapentaenoic acid (EPA) ethyl ester (460mg) and docosahexaenoic acid (DHA) ethyl ester (380mg). Excipient(s): may contain soya bean oil For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Capsule, soft _Product imported from the UK_ Soft, oblong, transparent gelatin capsules containing pale yellow oil. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Post Myocardial Infarction Adjuvant treatment in secondary prevention after myocardial infarction, in addition to other standard therapy (e.g. statins, antiplatelet medicinal products, betablockers, ACE inhibitors). Hypertriglyceridaemia Endogenous hypertriglyceridaemia as a supplement to diet when dietary measures alone are insufficient to produce an adequate response: type IV in monotherapy, type IIb/III in combination with statins, when control of triglycerides is insufficient. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Post Myocardial Infarction One capsule daily. Hypertriglyceridaemia Initial treatment two capsules daily. If adequate response is not obtained, the dose may be increased to four capsules daily. The capsules may be taken with food to avoid gastrointestinal disturbances. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 09/12/2010_ _CRN 2089705_ _page number: 1_ There is no information regarding the use of Omacor in children, in elderly patients over 70 years of age, or in patients with hepatic impairment _(see section 4.4), _and only limited information regarding the use in patients with renal impairment. 4.3 CONTRAIN Baca dokumen lengkapnya